Vandetanib
Overview
Vandetanib is an antineoplastic agent. It is a protein kinase inhibitor which inhibits the VEGFR-2, EGFR and RET tyrosine kinase. It is indicated in the treatment of medullary thyroid cancer.
Categories
No Categories Defined
Primary Characterstics
Indications
Back to top
Pharmacokinetics
Back to top
Contraindications
Back to top
Back to top
Side Effects
Back to top
Dosage
Vandetanib's dosage details are as follows:
| Dose
|
Single Dose
|
Frequency
|
Route
|
Instructions
|
Adult Dosage
|
| 300 to 300 mg | 300 (300) | 24 hourly | PO | Take with or without food at about the same time each day. Starting dose is 200 mg in patients with renal impairment. |
Paedriatic Dosage (20kg)
|
| No data regarding the Paedriatic dosage details of Vandetanib is available. |
Neonatal Dosage (3kg)
|
| No data regarding the neonatal dosage details of Vandetanib is available. |
High Risk Groups
Back to top
Warning / Precautions
Back to top
Storage Conditions
Back to top
Interference in Pathology
Back to top
Brands / Trade Names of
Vandetanib
Back to top
Previous Drug Generic - Next Drug Generic